330 related articles for article (PubMed ID: 26613809)
21. Thrombotic microangiopathies.
Rosove MH
Semin Arthritis Rheum; 2014 Jun; 43(6):797-805. PubMed ID: 24360024
[TBL] [Abstract][Full Text] [Related]
22. A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report.
Wei X; Li J; Zhan X; Tu L; Huang H; Wang Y
J Med Case Rep; 2022 Mar; 16(1):101. PubMed ID: 35241161
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy.
Scully M
Semin Thromb Hemost; 2016 Oct; 42(7):774-779. PubMed ID: 27648610
[TBL] [Abstract][Full Text] [Related]
24. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
Laurence J; Haller H; Mannucci PM; Nangaku M; Praga M; Rodriguez de Cordoba S
Clin Adv Hematol Oncol; 2016 Nov; 14 Suppl 11(11):2-15. PubMed ID: 27930620
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
Pecoraro C; Ferretti AV; Rurali E; Galbusera M; Noris M; Remuzzi G
Am J Kidney Dis; 2015 Dec; 66(6):1067-70. PubMed ID: 26409664
[TBL] [Abstract][Full Text] [Related]
26. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
27. Thrombotic Microangiopathy Syndromes-Common Ground and Distinct Frontiers.
Hanna RM; Henriksen K; Kalantar-Zadeh K; Ferrey A; Burwick R; Jhaveri KD
Adv Chronic Kidney Dis; 2022 Mar; 29(2):149-160.e1. PubMed ID: 35817522
[TBL] [Abstract][Full Text] [Related]
28. Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.
Mousseaux C; Joly BS; Mohamadou I; Arrestier R; Hertig A; Rafat C
BMC Nephrol; 2020 May; 21(1):204. PubMed ID: 32471388
[TBL] [Abstract][Full Text] [Related]
29. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.
Che M; Moran SM; Smith RJ; Ren KYM; Smith GN; Shamseddin MK; Avila-Casado C; Garland JS
Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703
[TBL] [Abstract][Full Text] [Related]
30. Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
Bitzan M; Hammad RM; Bonnefoy A; Al Dhaheri WS; Vézina C; Rivard GÉ
Pediatr Nephrol; 2018 Aug; 33(8):1437-1442. PubMed ID: 29728803
[TBL] [Abstract][Full Text] [Related]
31. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
Yoshida Y; Miyata T; Matsumoto M; Shirotani-Ikejima H; Uchida Y; Ohyama Y; Kokubo T; Fujimura Y
PLoS One; 2015; 10(5):e0124655. PubMed ID: 25951460
[TBL] [Abstract][Full Text] [Related]
32. Atypical hemolytic uremic syndrome: Laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations.
Hossain MA; Cheema A; Kalathil S; Bajwa R; Costanzo EJ; Cosentino J; Cheng J; Vachharajani T; Asif A
Saudi J Kidney Dis Transpl; 2018; 29(2):276-283. PubMed ID: 29657193
[TBL] [Abstract][Full Text] [Related]
33. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Kremer Hovinga JA; Heeb SR; Skowronska M; Schaller M
J Thromb Haemost; 2018 Apr; 16(4):618-629. PubMed ID: 29356300
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.
Cataland SR; Holers VM; Geyer S; Yang S; Wu HM
Blood; 2014 Jun; 123(24):3733-8. PubMed ID: 24695849
[TBL] [Abstract][Full Text] [Related]
35. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.
Schneppenheim R; Budde U; Oyen F; Angerhaus D; Aumann V; Drewke E; Hassenpflug W; Häberle J; Kentouche K; Kohne E; Kurnik K; Mueller-Wiefel D; Obser T; Santer R; Sykora KW
Blood; 2003 Mar; 101(5):1845-50. PubMed ID: 12393505
[TBL] [Abstract][Full Text] [Related]
36. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
37. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
Moake JL
Arch Pathol Lab Med; 2002 Nov; 126(11):1430-3. PubMed ID: 12421153
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity.
Valsecchi C; Mirabet M; Mancini I; Biganzoli M; Schiavone L; Faraudo S; Mane-Padros D; Giles D; Serra-Domenech J; Blanch S; Trisolini SM; Facchini L; Rinaldi E; Peyvandi F
Thromb Haemost; 2019 Nov; 119(11):1767-1772. PubMed ID: 31587247
[TBL] [Abstract][Full Text] [Related]
39. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.
Trojnar E; Józsi M; Szabó Z; Réti M; Farkas P; Kelen K; Reusz GS; Szabó AJ; Garam N; Mikes B; Sinkovits G; Mező B; Csuka D; Prohászka Z
Front Immunol; 2019; 10():240. PubMed ID: 30858847
[TBL] [Abstract][Full Text] [Related]
40. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
